Much as investors may wish it were true, it's not always the case that a
great drug, test or medical device meets with real commercial success.
Launching new med-tech products always involves an intricate dance
between efficacy, patient control (in other words, doctors' "turf"),
compliance, cost/benefit, and reimbursement. That could prove to be
especially relevant in the case of Exact Sciences (NASDAQ: EXAS) and its non-invasive Cologuard colorectal cancer test.
Please follow the link to read more:
For Exact Sciences, Approval May Be The Easy Part
No comments:
Post a Comment